|
TMX1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.49740000796339E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.00909999970023E-07 |
| Normal-vs-Stage2 |
5.810400E-04 |
| Normal-vs-Stage3 |
2.36460000468952E-08 |
| Normal-vs-Stage4 |
3.55110052474572E-10 |
| Stage1-vs-Stage2 |
6.859000E-01 |
| Stage1-vs-Stage3 |
1.775440E-01 |
| Stage1-vs-Stage4 |
2.623900E-03 |
| Stage2-vs-Stage3 |
2.025200E-01 |
| Stage2-vs-Stage4 |
7.844800E-03 |
| Stage3-vs-Stage4 |
5.991600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11000000302397E-08 |
| Normal-vs-AfricanAmerican |
6.443000E-03 |
| Normal-vs-Asian |
8.12270000039028E-07 |
| Caucasian-vs-AfricanAmerican |
3.818800E-01 |
| Caucasian-vs-Asian |
4.976600E-01 |
| AfricanAmerican-vs-Asian |
2.038600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.73770003625884E-09 |
| Normal-vs-Female |
4.51730000072814E-08 |
| Male-vs-Female |
1.726440E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.03739999998987E-06 |
| Normal-vs-Age(41-60Yrs) |
6.27950003107003E-09 |
| Normal-vs-Age(61-80Yrs) |
4.45050000186242E-08 |
| Normal-vs-Age(81-100Yrs) |
6.920400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.078990E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.341950E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.520000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.781400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.781600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.424200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.156990E-01 |
| Classical-VS-Follicular |
9.640600E-01 |
| Classical-VS-Other |
8.312100E-02 |
| Classical-VS-Normal |
7.82000000310035E-08 |
| Tall-VS-Follicular |
1.508440E-01 |
| Tall-VS-Other |
3.270000E-01 |
| Tall-VS-Normal |
1.79320000004424E-06 |
| Follicular-VS-Other |
1.552020E-01 |
| Follicular-VS-Normal |
7.5182000000007E-05 |
| Other-VS-Normal |
5.790300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.37649999953915E-07 |
| Normal-vs-N1 |
7.88760001757538E-09 |
| N0-vs-N1 |
2.942500E-02 |
|
|
